AVLNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Avalyn Pharma Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$23.33−0.33 (-1.39%)
Close on Oct 19, 2026
- Market cap
- $691.75M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 12, 2026 | Before market open | – | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | Jun 3, 2026 | Before market open | – | – | – |
Press releases
Announcements Avalyn Pharma filed with the SEC
Avalyn Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Results of operations · EX-99.1 to Form 8-K
Avalyn Completes Target Enrollment in Phase 2b MIST Trial of AP01 (Inhaled Pirfenidone) for Patients with Progressive Pulmonary Fibrosis
Regulation FD disclosure · EX-99.1 to Form 8-K
Avalyn Reports First Quarter 2026 Financial Results and Recent Business Highlights
Results of operations · EX-99.1 to Form 8-K